Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAGMATYK: Long-term Safety Study of Deucravacitinib vs Ustekinumab in Moderate-to-Severe Plaque Psoriasis
jRCT2031250528Phase 4Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 4, randomised, open-label trial in plaque psoriasis comparing Deucravacitinib arm with Stelara arm (2 arms). Primary endpoint: MACE. Started Nov 2025; status: recruiting.
02
Drugs
deucravacitinibustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2031250528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250528.